This analysis shows combined dynamic contrast-enhanced and dynamic susceptibility-contrast MRI enhances diagnostic accuracy in glioblastoma and brain metastases.
Key Points
Combined dynamic contrast-enhanced MRI and dynamic susceptibility-contrast MRI achieved excellent accuracy in distinguishing treatment-related effects from tumor progression.
The key metrics calculated included Ktrans_mean and rCBV_mean, with Ktrans_mean outperforming other imaging biomarkers.
This study enrolled patients with treated glioblastoma or brain metastases to assess the effectiveness of combined MRI sequences.
These findings suggest that improved diagnostic tools may help physicians evaluate treatment responses more effectively.